Development And Validation Of A Population-Specific Colorimetric Lamp Assay For Beta-Thalassemia Screening In West Java, Indonesia
International Journal of Drug Delivery Technology · 29.06.2026 · 16 (59s)
DOI: 10.25258/ijddt.16.59s.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 29.06.2026. Verfasst von Nauphar D und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Beta-thalassemia represents a major public health burden in Indonesia, where the country is classified within the 'Thalassemia Belt.' The Cirebon, Kuningan, Majalengka, and Indramayu (CKMI) sub-region of West Java accounts for an estimated 500–600 new transfusion-dependent cases annually. Gold-standard molecular diagnosis using reverse dot blot (RDB) and Sanger sequencing is accurate but requires advanced laboratory infrastructure, precluding its routine use in peripheral healthcare settings. Colorimetric Loop-Mediated Isothermal Amplification (C-LAMP) offers isothermal amplification with naked-eye result interpretation, making it highly suitable for front-line screening in peripheral settings as a complement to existing centralized molecular diagnostic services. This study aimed to develop and validate a population-specific C-LAMP kit targeting the four predominant HBB point mutations in the CKMI population.
Methods
HBB mutation profiling was performed on 30 transfusion-dependent thalassemia (TDT) patients from the CKMI region using GAP-PCR (alpha-globin deletions) and reverse dot blot (beta-globin mutations). Population-specific LAMP primer sets and synthetic gBlock positive controls were designed for four dominant mutations: CD26 (HbE), IVS1-5 (G→C), CD41/42 (–TTCT), and CD15 (G→A). The final C-LAMP kit was validated against 279 samples (92 thalassemia carriers/patients; 187 healthy controls) using RDB and Sanger sequencing as the gold standard. Due to the proprietary status of the primer and gBlock sequences (patent pending), specific oligonucleotide sequences are not disclosed in this publication; the design framework and functional validation data are reported.
Results
Population profiling confirmed that IVS1-5 (46.7%) and CD26/HbE (31.7%) are the dominant HBB alleles in the CKMI region. The IVS1-5/CD26 (HbE) compound heterozygous genotype accounted for 43.3% of cases. C-LAMP validation on 279 samples achieved: sensitivity 100%, specificity 99.47%, accuracy 99.64%, PPV 98.92%, NPV 100%, LR+ 188.0, and LR− 0.00. Overall concordance with the gold standard was 99.6% (278/279 samples).
Conclusions
The C-LAMP kit demonstrated near-perfect diagnostic performance for population-specific beta-thalassemia mutation detection. Its isothermal reaction, naked-eye result interpretation, and freedom from complex equipment make it a viable front-line screening platform that complements centralized molecular diagnostic services, extending thalassemia diagnostic capacity to peripheral and resource-limited healthcare facilities across Indonesia. This study establishes the first population-specific C-LAMP diagnostic kit designed for the West Java thalassemia mutation spectrum.
Zitieren
APA
D, N., PA, W., & Y, A. A. (2026). Development And Validation Of A Population-Specific Colorimetric Lamp Assay For Beta-Thalassemia Screening In West Java, Indonesia. International Journal of Drug Delivery Technology, 16(59s). https://doi.org/10.25258/ijddt.16.59s.29
Vancouver
D N, PA W, Y AA. Development And Validation Of A Population-Specific Colorimetric Lamp Assay For Beta-Thalassemia Screening In West Java, Indonesia. International Journal of Drug Delivery Technology. 2026;16(59s). doi:10.25258/ijddt.16.59s.29
BibTeX
@article{D2026,
author = {D, Nauphar and PA, Wahidiyat and Y, Ariani Aswin},
title = {Development And Validation Of A Population-Specific Colorimetric Lamp Assay For Beta-Thalassemia Screening In West Java, Indonesia},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {59s},
doi = {10.25258/ijddt.16.59s.29}
}
EUVIMED